Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial

Autor: Khalaf, Daniel J, Annala, Matti, Taavitsainen, Sinja, Finch, Daygen L, Oja, Conrad, Vergidis, Joanna, Zulfiqar, Muhammad, Sunderland, Katherine, Azad, Arun A, Kollmannsberger, Christian K, Eigl, Bernhard J, Noonan, Krista, Wadhwa, Deepa, Attwell, Andrew, Keith, Bruce, Ellard, Susan L, Le, Lyly, Gleave, Martin E, Wyatt, Alexander W, Chi, Kim N ^*

Publikováno v: In The Lancet Oncology December 2019 20(12):1730-1739

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

CDKN2A founder mutation in pancreatic ductal adenocarcinoma patients without cutaneous features of Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome

Autor: Cremin, Carol, Howard, Sarah, Le, Lyly, Karsan, Aly, Schaeffer, David F, Renouf, Daniel, Schrader, Kasmintan A

Background: Approximately 5% to 10% of pancreatic ductal adenocarcinoma (PDAC) has a hereditary basis. In most of these defined hereditary cancer syndromes, PDAC is not the predominant cancer type. Traditional criteria for publicly funded genetic tes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5c852ab8a112e197b319ee1eb425c687

A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209.

Autor: Eigl BJ; BC Cancer Agency, Vancouver, BC, Canada., Chi K; BC Cancer Agency, Vancouver, BC, Canada., Tu D; Canadian Cancer Trials Group, Kingston, ON, Canada., Hotte SJ; Juravinski Cancer Centre, Hamilton, ON, Canada., Winquist E; London Health Sciences Centre, London, ON, Canada., Booth CM; Cancer Centre of Southeastern Ontario, Kingston, ON, Canada., Canil C; Ottawa Regional Cancer Center, Ottawa, ON, Canada., Potvin K; London Health Sciences Centre, London, ON, Canada., Gregg R; Canadian Cancer Trials Group, Kingston, ON, Canada., North S; Cross Cancer Centre, Edmonton, AB, Canada., Zulfiqar M; BC Cancer Agency, Vancouver, BC, Canada., Ellard S; BC Cancer Agency, Kelowna, BC, Canada., Ruether JD; Tom Baker Cancer Centre, Calgary, AB, Canada., Le L; BC Cancer Agency, Surrey, BC, Canada., Kakumanu AS; Cancer Care Manitoba, Winnipeg, MB, Canada., Salim M; Regina Cancer Centre, Regina, SK, Canada., Allan AL; London Health Sciences Centre, London, ON, Canada., Feilotter H; Canadian Cancer Trials Group, Kingston, ON, Canada., Theis A; Canadian Cancer Trials Group, Kingston, ON, Canada., Seymour L; Canadian Cancer Trials Group, Kingston, ON, Canada.

Publikováno v: Oncotarget [Oncotarget] 2018 Jan 17; Vol. 9 (8), pp. 8155-8164. Date of Electronic Publication: 2018 Jan 17 (Print Publication: 2018).